{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:10:06Z","timestamp":1757617806938,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-00993-4","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T10:16:51Z","timestamp":1745057811000},"page":"641-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of rapidly progressive IgA nephropathy after SARS-CoV-2 vaccination, successfully treated with cyclophosphamide"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5787-6888","authenticated-orcid":false,"given":"Risa","family":"Masaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naobumi","family":"Mise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"993_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s10157-021-02157-x","volume":"26","author":"K Matsuzaki","year":"2022","unstructured":"Matsuzaki K, et al. Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 2022;26:316\u201322.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"993_CR2","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ekir.2022.03.025","volume":"7","author":"J Zan","year":"2022","unstructured":"Zan J, et al. Safety evaluation of COVID-19 vaccine in patients with IgA nephropathy or IgA vasculitis nephritis. Kidney Int Rep. 2022;7(6):1435\u20136.","journal-title":"Kidney Int Rep"},{"key":"993_CR3","doi-asserted-by":"crossref","unstructured":"Hui Zhuan Tan et al. (2021) Is COVID-19 vaccination unmasking glomerulonephritis?. Kidney Int 100: 2 469\u2013471.","DOI":"10.1016\/j.kint.2021.05.009"},{"issue":"3","key":"993_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.34067\/KID.0000000000000073","volume":"4","author":"Y Radhakrishnan","year":"2023","unstructured":"Radhakrishnan Y, Zand L. New onset glomerular disease post\u2013COVID-19 vaccination: is there a link? Kidney. 2023;4(3):294\u20136.","journal-title":"Kidney"},{"issue":"12","key":"993_CR5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1681\/ASN.2022030258","volume":"33","author":"M Canney","year":"2022","unstructured":"Canney M, et al. A population-based analysis of the risk of glomerular disease relapse after COVID-19 vaccination. J Am Soc Nephrol. 2022;33(12):2247\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"33","key":"993_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030066","volume":"101","author":"E Ran","year":"2022","unstructured":"Ran E, et al. New-onset crescent IgA nephropathy following the CoronaVac vaccine: a case report. Medicine. 2022;101(33): e30066.","journal-title":"Medicine"},{"issue":"46","key":"993_CR7","volume":"102","author":"T Uchida","year":"2023","unstructured":"Uchida T, et al. Acute exacerbation of immunoglobulin A nephropathy complicated by alveolar hemorrhage after coronavirus disease 2019 vaccination: a case report. Medicin. 2023;102(46): e36091.","journal-title":"Medicin"},{"issue":"2","key":"993_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.kint.2021.05.017","volume":"100","author":"A Sekar","year":"2021","unstructured":"Sekar A, et al. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int. 2021;100(2):473\u20134.","journal-title":"Kidney Int"},{"key":"993_CR9","doi-asserted-by":"crossref","unstructured":"Elio Junior Feghali et al. (2021) De-novo antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273(Moderna) Vaccine for COVID-19. Cureus 13: 11 19616","DOI":"10.7759\/cureus.19616"},{"issue":"12","key":"993_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.762006","volume":"30","author":"S Hakroush","year":"2021","unstructured":"Hakroush S, et al. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizre-BioNTech COVID-19 mRNA vaccination. Front Immunol. 2021;30(12): 762006.","journal-title":"Front Immunol"},{"issue":"5","key":"993_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.kint.2023.08.013","volume":"104","author":"M Lee","year":"2023","unstructured":"Lee M, et al. The nucleotide-sensing Toll-Like Receptor 9\/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy. Kidney Int. 2023;104(5):943\u201355.","journal-title":"Kidney Int"},{"key":"993_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","volume":"21","author":"JR Teijaro","year":"2021","unstructured":"Teijaro JR, et al. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195\u20137.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"993_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4155\/tde-2016-0006","volume":"7","author":"AM Richmuth","year":"2016","unstructured":"Richmuth AM, et al. mRNA vaccine delivery using lipid nanoparticles. Deliv. 2016;7(5):319\u201334.","journal-title":"Deliv"},{"issue":"2","key":"993_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13730-022-00743-w","volume":"12","author":"K Ota","year":"2023","unstructured":"Ota K, et al. Comparison of renal histopathology in three patients with gross hematuria after SARS-CoV-2 vaccination. CEN Case Rep. 2023;12(2):176\u201383.","journal-title":"CEN Case Rep"},{"key":"993_CR15","first-page":"CD003965","volume":"3","author":"P Natale","year":"2020","unstructured":"Natale P, et al. Immunosuppressive agents for treating IgA nephropathy. Database Syst Rev. 2020;3:CD003965.","journal-title":"Database Syst Rev"},{"issue":"23","key":"993_CR16","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225\u201336.","journal-title":"N Engl J Med"},{"issue":"4","key":"993_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10157-015-1223-y","volume":"20","author":"Y Yuzawa","year":"2016","unstructured":"Yuzawa Y, et al. Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clin Exp Nephrol. 2016;20(4):511\u201335.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"993_CR18","doi-asserted-by":"publisher","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","volume":"6","author":"F Hou","year":"2023","unstructured":"Hou F, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254054.","journal-title":"JAMA Netw Open"},{"issue":"10417","key":"993_CR19","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomized, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390.","journal-title":"Lancet"},{"issue":"10084","key":"993_CR20","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"C Bengt","year":"2017","unstructured":"Bengt C, Fellstr\u00f6m at al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomized, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327.","journal-title":"Lancet"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-00993-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-00993-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-00993-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:08:28Z","timestamp":1757160508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-00993-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-00993-4","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This paper does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the patient for the publication of this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}